SCM
SUPN icon

Shelton Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Shelton Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,197
Closed -$262K – 884
2018
Q3 		$262K Buy
5,197
+191
+4% +$9.43K 0.01% 691
2018
Q2 		$300K Buy
5,006
+477
+11% +$24.7K 0.02% 564
2018
Q1 		$207K Buy
+4,529
New +$189K 0.01% 767
2017
Q3 		– Sell
-4,979
Closed -$215K – 873
2017
Q2 		$215K Buy
+4,979
New +$177K 0.02% 780

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Shelton Capital Management's SUPN Position: Q4 2018 in Review

Shelton Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 5,197 shares — an estimated $262K sold.

Shelton Capital Management first reported a position in SUPN in Q2 2017 and held it in 4 quarters. The position peaked at $300K in Q2 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Shelton Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Shelton Capital Management sold 5,197 Supernus Pharmaceuticals shares in Q4 2018, an estimated $262K.
  • Shelton Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Shelton Capital Management's Supernus Pharmaceuticals position peaked at $300K in Q2 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Shelton Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.